Literature DB >> 32871745

Malignant Priapism - What Do We Know About It?

Dragos Marcu1,2, Lucian Iorga1, Dan Mischianu1,2,3, Nicolae Bacalbasa4,5,6, Irina Balescu7, Ovidiu Bratu1,2,3.   

Abstract

Malignancy as an etiological factor involved in priapism pathogenesis is rare. Malignant priapism (MP) can arise as a result of penile tumor invasion, either from primary penile tumors or from metastatic penile tumors, or due to hematological malignancies. Non-urological penile metastases are associated with significant worse prognosis compared to urological penile metastases, the appearance of priapism in such cases affecting even more the prognosis and the survival of these patients. Patients diagnosed with hematological malignancies and priapism present significant higher survival rates compared to those who develop MP in the context of a non-hematological malignancy, this being related to the fact that hematological malignancies are more sensitive to chemo- and radiotherapy. Most malignant priapism cases are ischemic; therefore the management should be based on the initial steps of the IP therapeutic protocol. Considering the trigger factor that has led to the priapic event specific oncologic treatment can be added as well. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Malignant priapism; hematological malignancy; penile tumors; review

Mesh:

Year:  2020        PMID: 32871745      PMCID: PMC7652445          DOI: 10.21873/invivo.12033

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  37 in total

Review 1.  Evaluation and management of priapism: 2009 update.

Authors:  Yun-Ching Huang; Ahmed M Harraz; Alan W Shindel; Tom F Lue
Journal:  Nat Rev Urol       Date:  2009-05       Impact factor: 14.432

2.  The use of high-resolution magnetic resonance imaging in the management of patients presenting with priapism.

Authors:  David J Ralph; Nigel C Borley; Clare Allen; Alex Kirkham; Alex Freeman; Suks Minhas; Asif Muneer
Journal:  BJU Int       Date:  2010-12       Impact factor: 5.588

3.  Penile prosthesis insertion in patients with refractory ischaemic priapism: early vs delayed implantation.

Authors:  Evangelos Zacharakis; Gulio Garaffa; Amr A Raheem; Andrew N Christopher; Asif Muneer; David J Ralph
Journal:  BJU Int       Date:  2014-10       Impact factor: 5.588

4.  Malleable penile prosthesis is a cost-effective treatment for refractory ischemic priapism.

Authors:  Timothy J Tausch; Lee C Zhao; Allen F Morey; Jordan A Siegel; Michael J Belsante; Casey A Seideman; James R Flemons
Journal:  J Sex Med       Date:  2014-12-23       Impact factor: 3.802

5.  Leukapheresis in management hyperleucocytosis induced complications in two pediatric patients with chronic myelogenous leukemia.

Authors:  Dobrila Veljković; Milos Kuzmanović; Dragan Mićić; Olivera Šerbić-Nonković
Journal:  Transfus Apher Sci       Date:  2012-04-03       Impact factor: 1.764

6.  Successful use of terbutaline in persistent priapism in a 12-year-old boy with chronic myeloid leukemia.

Authors:  Ajay Gupta; Tulika Seth; Anuradha Gupta
Journal:  Pediatr Hematol Oncol       Date:  2009-01       Impact factor: 1.969

7.  Malignant priapism due to penile metastases: Case series and literature review.

Authors:  Francesco De Luca; Evangelos Zacharakis; Majed Shabbir; Angela Maurizi; Emy Manzi; Antonio Zanghì; Carlo De Dominicis; David Ralph
Journal:  Arch Ital Urol Androl       Date:  2016-07-04

Review 8.  Management of refractory ischemic priapism: current perspectives.

Authors:  Marco Capece; Arianna Gillo; Andrea Cocci; Giulio Garaffa; Massimiliano Timpano; Marco Falcone
Journal:  Res Rep Urol       Date:  2017-08-29

Review 9.  Recent advances in the management of priapism.

Authors:  Asif Muneer; Hussain M Alnajjar; David Ralph
Journal:  F1000Res       Date:  2018-01-10

Review 10.  Prognosis of men with penile metastasis and malignant priapism: a systematic review.

Authors:  Andrea Cocci; Oliver W Hakenberg; Tommaso Cai; Gabriella Nesi; Lorenzo Livi; Beatrice Detti; Andrea Minervini; Girolamo Morelli; Marco Carini; Sergio Serni; Mauro Gacci
Journal:  Oncotarget       Date:  2017-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.